References
- Ang, C., Fen, H.E., Sub, H.E., 2006. Pharmacokinetics of galantamine Hbr in plasma and brain of mice. Chin. J. Pharm. 37, 55-61.
- Bankar, U.V., Osborne, D.W., 1995. Transdermal drug product development. Technomic Publishing AG, Switzerland. 165-179.
- Breuer, M.M., 1979. The interaction between surfactants and keratinous tissues. J. Soc. Cosmet. 30, 41-64.
- Bohn, M., Kraemer, K.T., 2000. Dermatopharmacology of ciclopirox nail laquer topical solution 8% in the treatment of onychomycosis. J. Am. Aca. Dermatol. 43, 57-69. https://doi.org/10.1067/mjd.2000.109072
- Cho, Y.-J., Choi, H.-K., 1998. Enhancement of percutaneous absorption of ketoprofen: Effect of vehicles and adhesive matrix. Int. J. Pharm. 169, 95-104. https://doi.org/10.1016/S0378-5173(98)00115-X
- Choi, H-K., Angello, J., 1994. The Mathematical analysis and optimization of a flow through diffusion cell system. Pharm. Res. 11, 595-599. https://doi.org/10.1023/A:1018991221647
- Corey-Bloom, J., 2003. Galantamine: a review of its use in Alzheimer's disease and vascular dementia. Int. J. Clin. Pract. 57, 219-223.
- Coyle, J., Kershaw, P., 2001. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimers disease. Biol. Psychiatry. 49, 289-299 https://doi.org/10.1016/S0006-3223(00)01101-X
- Cummings, J.L., 2003. Use of cholinesterase inhibitors in clinical practice: Evidence-based recommendations. Am. J. Geriatr. Psychiatry. 11, 131-145.
- Erkinjuntti, T., 2002. Treatment options: The latest evidence with galantamine. J. Neurol .Sci. 203, 125-130. https://doi.org/10.1016/S0022-510X(02)00267-8
- Fulton, B., Benfield, P., 1996. Galanthamine. Drugs & Aging. 9, 60-67. https://doi.org/10.2165/00002512-199609010-00006
- Furuishi, T., Io, T., Fukami, T., Suzuki, T., Tomono, K., 2008. Formulation and in vitro evaluation of pentazocine transdermal drug delivery system. Biol. Pharm. Bull. 31, 1439-1443. https://doi.org/10.1248/bpb.31.1439
- Ghosh, T.K., Pfister, W.R., Yum, S.I., 1997. Transdermal and topical drug delivery systems. In: Pfister, W.R. (Ed.), Transdermal and Dermal Therapeutic Systems. Current Status. Interpharm Press, Illinois. 38-59.
- Heinrich, M., Teoh, H.L., 2004. Galantamine from snowdrop the development of a modern drug against Alzheimers disease from local Caucasian knowledge. J. Ethnopharmacol. 92, 147-162. https://doi.org/10.1016/j.jep.2004.02.012
- Imani, M., Fard, F.L., Taghezade, S.M., Takrousta, M., 2010. Effect of adhesive layer thickness and drug loading on estradiol Crystallization in a Transdermal Drug Delivery System. AAPS Pharm Sci Tech. 11, 1268-1275. https://doi.org/10.1208/s12249-010-9494-9
- Inoue, K., Okada, J., Sugibayashi, K., 2005. Enhancement of skin permeation of ketoprofen by supersaturation generated by amorphous form of the drug. J. Control. Release. 108, 306-318. https://doi.org/10.1016/j.jconrel.2005.08.008
- Kays, L.A., Sileno, A.P., Brandt, G.C., Foerder, C.A., Quay, S.C., 2007. In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Int. J. Pharm. 335, 138-146. https://doi.org/10.1016/j.ijpharm.2006.11.013
- Kim, J.-H., Lee, C.H., Choi, H.-K., 2002. Transdermal delivery of physostigmine: Effect of enhancer and pressure sensitive adhesives. Drug Dev. Ind. Pharm. 28, 833-839. https://doi.org/10.1081/DDC-120005629
- Kim, J.-H., Cho Y.-J., Choi, H.-K., 2000. Effect of vehicles and pressure sensitive adhesives on the permeation of tacrine across hairless mouse skin. Int. J. Pharm. 196, 105-113. https://doi.org/10.1016/S0378-5173(99)00449-4
-
Migliaccio, W.K., Getsios, D., Caro, J.J., Ishak, K.J., Brien, J.A.O., Papadopoulos, G., 2003. Economic evaluation of galantamine in the treatment of mild to moderate
$Alzheimer^{\circ}Os$ disease in the United States. Clin. Ther. 25, 1806-1825. https://doi.org/10.1016/S0149-2918(03)80171-6 - Morimoto, Y., Kokubo, T., Sugibayashi, K., 1992. Diffusion of drug in acrylic type pressure sensitive adhesive matrix. II. Influence of interaction. J. Control. Release. 18, 113-121. https://doi.org/10.1016/0168-3659(92)90180-Y
- Nordberg, A., Svensson, A.L., 1999. Cholinesterase inhibitors in the treatment of Alzheimer’s disease: a comparison of tolerability and pharmacology. Drug Safety. 20, 146.
- Poirier, J., 2002. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int. J. Clin. Pract. Suppl. 127, 6-19.
- Raskind, M.A., Peskind, E.R., Wessel, T., Yuan, W., 2000. Galantamine in AD, a 6-month randomized, placebo-controlled trial with a 6-month extension. The galantamine USA-1 Study Group. Neurology. 54, 2261-2268. https://doi.org/10.1212/WNL.54.12.2261
- Roy, S.D., Gutierrez, M., Flynn, G.L., Cleary G.W., 1996. Controlled transdermal delivery of fentanyl: Characterizations of pressure sensitive adhesives for matrix patch design. J. Pharm. Sci., 85, 491-495. https://doi.org/10.1021/js950415w
- Scott, L.J., Goa, K.L., 2000. Galantamine: a review of its use in Alzheimer’s disease. Drugs. 60, 1095-1122. https://doi.org/10.2165/00003495-200060050-00008
- Sramek, J.J., Frackiewicz, E.J., Cutler, N.R., 2000. Review of acetylcholinesterase inhibitor galantamine. Expert Opin. Investig. Drugs. 9, 2393-2402. https://doi.org/10.1517/13543784.9.10.2393
- Subedi, R.K., Jang, J.H., Kim, Jae-II, Park, Y.J., Choi, H.-K., 2010. Formulation and evaluation of transdermal patch containing sibutramine. J. Kor. Pharm. Sci. 40, 33-38.
- Subedi, R.K., Seaung, Y.O., Chun, M.K., Choi, H.-K., 2010. Recent Advances in Transdermal Drug Delivery. Arch. Pharm. Res. 33, 339-351. https://doi.org/10.1007/s12272-010-0301-7
- Thomas, B.J., Finnin, F.C., 2004. The transdermal revolution. Drug Discov. Today. 9, 697-703. https://doi.org/10.1016/S1359-6446(04)03180-0
- Walters, K.A., Walker, M., Olejnik, O., 1987. Non-ionic surfactant effects on hairless mouse skin permeability characteristics. J. Pharm. Pharmacol. 40, 525-529.
- Wilking, S.M., Husberg, M.L., Ko, C.U., Wick, S.M., 1994. The effect of excipients on the physical properties of selected acrylate, polyisobutylene and silicone pressure sensitive adhesives commonly utilized in transdermal 20 drug delivery systems. Pharm. Res. 11, S226. https://doi.org/10.1023/A:1018999106684
- Williams, A.C., Barry, B.W., 2004. Penetration enhancers. Adv. Drug Deliver. Rev. 56, 603-618. https://doi.org/10.1016/j.addr.2003.10.025
- Wokovich, A.M., Prodduturi, S., Doub, W.H., Hussain, A.S., Buhse, L.F., 2006. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. Eur. J. Pharm. Biopharm. 64, 1-8. https://doi.org/10.1016/j.ejpb.2006.03.009
- Zarotsky, V., Sramek, J.J., Cutler, N.R., 2001. Galantamine hydrobromide: an agent for Alzheimer’s disease. Am. J. Health-Syst. Pharm. 60, 446-452.
Cited by
- Development of cataplasmic transdermal drug delivery system containing eutectic mixture of lidocaine and prilocaine vol.42, pp.3, 2012, https://doi.org/10.1007/s40005-012-0023-6